Charlottesville, United States
LumaCyte, founded in 2012, is challenging conventional approaches in biotech with its groundbreaking Laser Force Cytology™ technology. This United States-based company focuses on label-free single cell analysis, a vital tool for various sectors within biotechnology and healthcare.
The technology eliminates the need for antibody or genetic labeling, offering a more refined analysis of intrinsic cellular properties. This innovation serves a wide array of applications, including vaccine creation, gene therapy, cancer research, and biomanufacturing — sectors currently witnessing a surge in demand for precision and efficiency.
Recently securing a Series B investment on 06 September 2023, with backing from Malvern Panalytical, LumaCyte is well-positioned for growth. It leverages Big Data and cloud computing to enable deep insights into biological systems, potentially maximizing yield and enhancing quality across its application spectrum.
Investors might find LumaCyte an attractive prospect due to its unique technology and broad market application, promising a transformative impact on the status quo of bioanalytics.
